The promise of allosteric kinase inhibition

This is the authors' abstract. We don't add key points for this paper.

In this issue of Blood, Yeung et al 1 report high molecular response rates and good tolerability of the first-in-class allosteric BCR::ABL1 inhibitor asciminib in a single-arm phase 2 study of 101 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML), thereby bolstering the case for asciminib as a first-line treatment option.